Sudden Cardiac Death & Cardiac Conditions in Athletes / Pre-Participation Screening

When the work-up confirms or strongly suspects disease, the decision about participation follows a recognised framework:

• The historical model was restrictive. Consensus documents (the 36th Bethesda Conference and the European Society of Cardiology recommendations) traditionally disqualified athletes with conditions such as HCM, ARVC and the long-QT syndromes from most competitive sport.
• The modern model is shared decision-making. Contemporary guidance (AHA/ACC and ESC sports-cardiology statements) has moved toward individualised risk assessment and shared, informed decision-making with the athlete (and, in minors, the family), rather than automatic blanket disqualification - weighing the specific diagnosis, symptoms, risk markers, sport type/intensity and the athlete's own values.
• Temporary versus permanent restriction. Some conditions need only temporary restriction - e.g. myocarditis, where abstention from exercise for roughly three to six months with re-evaluation is standard
  • while others may need long-term modification, treatment (e.g. beta-blockade in long-QT) or an ICD before any return.
• Competitive vs recreational participation are judged differently, and decisions are best made by, or with, a cardiologist experienced in athletes; document the discussion (medico-legal importance). General return-to-sport testing and criteria are developed in Return to Sport Criteria; condition-specific cardiac eligibility belongs with the cardiology guidance for each diagnosis.

The overlap between physiological cardiac adaptation and cardiac disease, the influence of age, sex and ethnicity, and the need for careful interpretation and ongoing surveillance come from the cited Sivalokanathan review. The survival odds ratios for bystander presence, CPR and AED use are the cited Michelland meta-analysis of 28 studies - all non-randomised, so these are associations rather than demonstrated causal effects, with GRADE certainty rated moderate. The incidence figures and the observations about AED signposting and medical plans come from the cited Bassi review, which is a narrative review rather than a pooled analysis, so its rates should be read as reported ranges rather than precise pooled estimates.

The argument that the low event rate is what drives the screening debate is an inference drawn from putting those incidence figures beside the debate rather than a conclusion any of the cited papers states. No verified figure was identified for the mortality benefit of ECG-inclusive versus history-and-examination screening, so none is quoted and the debate is left described rather than settled.

The specific causes of SCD in young versus older athletes, the International athlete ECG criteria, and the shift from blanket disqualification to shared decision-making are standard, well-established teaching. No dedicated topic on hypertrophic cardiomyopathy, commotio cordis or pre-participation evaluation exists in the library, so those are covered here rather than deferred. (See also Return to Sport Criteria.)